FTH Faeth Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1829802 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-775.6%
TTM EPS YoY-17.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-229.6%
ROA-204.7%
ROIC (approx.)-214.2%
Asset turnover—
Leverage & solvency
Liabilities / assets6.2%
Debt / equity0.00x
Current ratio16.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-162.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| SG&A expense | $11.33M | $13.04M | $18.77M | $19.80M | $15.82M |
| Operating income | -$22.29M | -$32.61M | -$37.06M | -$50.19M | -$37.48M |
| Interest expense | $32,000 | $90,000 | $144,000 | $219,000 | $670,000 |
| Pretax income | -$21.09M | -$30.16M | — | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$21.09M | -$30.16M | -$34.10M | -$48.59M | -$36.79M |
| EBITDA | -$22.17M | -$32.06M | -$36.49M | -$49.57M | -$36.80M |
| EPS (basic) | -16.72 | -24.01 | -1.22 | -1.58 | -1.33 |
| EPS (diluted) | -16.72 | -24.01 | -1.22 | -1.58 | -1.33 |
| Weighted avg. shares (diluted) | 1.26M | 1.26M | 27.95M | 30.70M | 27.71M |
| Balance sheet | |||||
| Cash & equivalents | $8.67M | $9.99M | $13.01M | $17.80M | $7.16M |
| Short-term investments | $12.52M | $31.34M | $52.75M | $89.32M | $140.46M |
| Current assets | $21.51M | $41.93M | $67.25M | $108.59M | $148.54M |
| PP&E, net | $82,000 | $417,000 | $1.17M | $2.05M | $4.64M |
| Total assets | $22.90M | $45.36M | $74.37M | $118.38M | $153.22M |
| Current liabilities | $4.25M | $5.45M | $5.64M | $9.07M | $4.89M |
| Total liabilities | $4.31M | $6.97M | $9.48M | $14.97M | $6.71M |
| Shareholders' equity | $18.59M | $38.39M | $64.89M | $103.41M | $146.51M |
| Shares outstanding | 1.26M | 1.26M | 25.03M | 30.76M | 30.61M |
| Cash flow statement | |||||
| Operating cash flow | -$20.45M | -$24.67M | -$32.02M | -$39.03M | -$30.26M |
| Capital expenditure | $16,000 | $146,000 | $180,000 | $321,000 | $2.03M |
| Free cash flow | -$20.47M | -$24.82M | -$32.20M | -$39.35M | -$32.28M |
| Investing cash flow | $19.77M | $22.44M | $38.41M | $49.95M | -$143.12M |
| Financing cash flow | -$645,000 | -$787,000 | -$11.17M | -$287,000 | $163.94M |
| Depreciation & amortization | $122,000 | $551,000 | $571,000 | $614,000 | $685,000 |
| Stock-based compensation | $1.27M | $3.13M | $4.45M | $5.81M | $5.66M |
| Share buybacks | — | — | $10.38M | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.